Your browser is no longer supported. Please, upgrade your browser.
Settings
RNN Rexahn Pharmaceuticals, Inc. daily Stock Chart
RNN [NYSE]
Rexahn Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.04 Insider Own2.50% Shs Outstand233.49M Perf Week-7.69%
Market Cap98.07M Forward P/E- EPS next Y-0.09 Insider Trans-2.45% Shs Float230.21M Perf Month-0.12%
Income-9.30M PEG- EPS next Q-0.02 Inst Own9.50% Short Float6.80% Perf Quarter128.26%
Sales- P/S- EPS this Y45.70% Inst Trans-83.70% Short Ratio2.42 Perf Half Y141.24%
Book/sh0.07 P/B6.00 EPS next Y-12.50% ROA-41.40% Target Price2.33 Perf Year32.66%
Cash/sh0.09 P/C4.83 EPS next 5Y- ROE-55.30% 52W Range0.13 - 0.71 Perf YTD195.98%
Dividend- P/FCF- EPS past 5Y18.90% ROI- 52W High-40.85% Beta-0.30
Dividend %- Quick Ratio11.10 Sales past 5Y- Gross Margin- 52W Low230.71% ATR0.06
Employees20 Current Ratio11.10 Sales Q/Q- Oper. Margin- RSI (14)43.26 Volatility10.04% 12.50%
OptionableNo Debt/Eq0.00 EPS Q/Q85.30% Profit Margin- Rel Volume0.31 Prev Close0.43
ShortableYes LT Debt/Eq0.00 EarningsMar 13 AMC Payout- Avg Volume6.46M Price0.42
Recom1.70 SMA20-20.02% SMA506.76% SMA20067.48% Volume2,010,796 Change-1.64%
Apr-06-17Resumed Rodman & Renshaw Buy $2
Mar-20-15Initiated MLV & Co Buy $1.25
Dec-28-12Initiated Burrill Institutional Research Mkt Outperform $1
Jan-18-12Resumed Rodman & Renshaw Mkt Perform
Jun-16-11Resumed Brean Murray Buy $3
Dec-02-10Initiated Brean Murray Buy $3
Apr-13-17 09:00AM  Rexahn Announces 1-for-10 Reverse Stock Split GlobeNewswire -26.14%
Mar-31-17 12:00PM  Penny Stocks to Watch for April 2017 (ATRS, WRN) Investopedia +5.81%
12:00PM  Penny Stocks to Watch for April 2017 (ATRS, WRN) at Investopedia
Mar-28-17 09:30AM  BioDelivery Sciences International and Rexahn Pharmaceuticals See Share Values Rise Slightly Accesswire
Mar-16-17 09:30AM  Trade Volume Can Speak a Lot About Momentum of a Stock Accesswire
08:35AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Moves Up 5.4% Zacks
Mar-02-17 01:04PM  REXAHN PHARMACEUTICALS, INC. Financials
Feb-27-17 09:00AM  Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update GlobeNewswire +8.32%
Feb-24-17 04:19PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Feb-23-17 09:00AM  Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin in Patients with Metastatic Triple Negative Breast Cancer GlobeNewswire
Feb-06-17 09:00AM  Rexahn Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Accesswire
Jan-20-17 09:00AM  Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium GlobeNewswire +5.75%
Jan-03-17 09:00AM  Rexahn Pharmaceuticals to Present at Biotech Showcase 2017 GlobeNewswire
Nov-25-16 04:04PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Shareholder Director Nominations
Nov-07-16 09:11AM  Rexahn reports 3Q loss
09:00AM  Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-16 04:18PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report +5.40%
Oct-31-16 09:00AM  Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 A Cancer Cell Specific Anticancer Agent GlobeNewswire
Oct-26-16 09:00AM  Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of Docetaxel for the Targeted Treatment of Solid Tumors GlobeNewswire
Oct-11-16 09:14PM  Rexahn Pharmaceuticals Nears 52-Week Low (RNN) Investopedia
09:14PM  Rexahn Pharmaceuticals Nears 52-Week Low (RNN) at Investopedia
Oct-10-16 07:00AM  Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress GlobeNewswire
Oct-06-16 02:19PM  Rexahn Pharmaceuticals to Present Trial Data (RNN) Investopedia
02:19PM  Rexahn Pharmaceuticals to Present Trial Data (RNN) at Investopedia
Oct-04-16 09:15AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
09:00AM  Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress GlobeNewswire
Sep-26-16 10:34AM  Rexahn Pharmaceuticals (RNN) Sees Hammer Chart Pattern: Time to Buy?
Sep-20-16 04:59PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-14-16 09:08AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ -10.79%
09:00AM  Rexahn Announces $6 Million Registered Direct Offering GlobeNewswire
Sep-12-16 09:09AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:00AM  Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer GlobeNewswire
Sep-07-16 09:00AM  Rexahn Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016 GlobeNewswire
Aug-08-16 09:15AM  Rexahn reports 2Q loss
09:00AM  Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial and Operational Results GlobeNewswire
Aug-05-16 04:11PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Jul-11-16 09:09AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:00AM  Rexahn Pharmaceuticals Strengthens Leadership Team GlobeNewswire
Jun-10-16 05:04PM  Rexahn Pharmaceuticals, Inc. :RNN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016
04:02PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
Jun-06-16 09:02AM  Rexahn Pharmaceuticals Presents Clinical Data for Three Novel Targeted Oncology Programs at the 2016 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-23-16 09:37AM  Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting GlobeNewswire
May-19-16 09:20AM  Rexahn Drugs Deal a Death Blow to Solid Tumor Cancer
May-09-16 09:15AM  Rexahn reports 1Q loss
09:00AM  Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
May-06-16 04:31PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Apr-28-16 09:00AM  ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report Marketwired
Apr-20-16 09:02AM  Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the 2016 American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-13-16 11:02AM  Rexahn Pharmaceuticals to Present at the 2016 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-29-16 09:19AM  Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral Anti-Cancer Therapeutic RX-3117 in the Treatment of Pancreatic and Bladder Cancer at noodls
09:00AM  Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral Anti-Cancer Therapeutic RX-3117 in the Treatment of Pancreatic and Bladder Cancer GlobeNewswire
Mar-24-16 09:10AM  Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress at noodls -7.35%
09:00AM  Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress GlobeNewswire
Mar-14-16 09:51AM  Rexahn reports 4Q loss
09:00AM  Rexahn Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
06:10AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-02-16 05:51PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-29-16 02:00PM  13G Filing: Sabby Capital Opens Large Position in Rexahn Pharmaceuticals, Inc. (RNN) at Insider Monkey -5.69%
Feb-26-16 09:35AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ
09:00AM  Rexahn Announces $5 Million Registered Direct Offering GlobeNewswire
Feb-23-16 11:45AM  Oral is Better: Rexahn Astounds with New Cancer Data Accesswire +11.09%
Feb-08-16 09:00AM  Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin® Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma GlobeNewswire -7.11%
Feb-01-16 09:31AM  Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at noodls +5.59%
09:00AM  Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 GlobeNewswire
Jan-25-16 09:17AM  Rexahn Pharmaceuticals Announces Supinoxin Poster Presentations at the 2016 Gastrointestinal Cancers Symposium at noodls
09:00AM  Rexahn Pharmaceuticals Announces Supinoxin Poster Presentations at the 2016 Gastrointestinal Cancers Symposium GlobeNewswire
Jan-22-16 09:00AM  BioWatch News' Alan Leong Interviewed by The Life Sciences Report Marketwired +11.41%
Jan-12-16 09:00AM  New Preclinical Data for Supinoxin Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition GlobeNewswire
Jan-11-16 09:00AM  Rexahn Pharmaceuticals Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study GlobeNewswire
Jan-05-16 09:00AM  Rexahn Pharmaceuticals to Present at Biotech Showcase 2016 GlobeNewswire
Dec-18-15 09:00AM  BioNap Consulting's Jason Napodano Interviewed by The Life Sciences Report Marketwired -9.76%
Dec-14-15 09:00AM  Rexahn Pharmaceuticals Announces New Data for Supinoxin Showing Potent Tumor Growth Inhibition GlobeNewswire
Nov-23-15 03:07PM  Biotechs Under 20 Dollars Poised to Breakout Accesswire +5.41%
Nov-12-15 05:12PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-11-15 09:00AM  Rexahn Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference on November 18, 2015 GlobeNewswire
Nov-06-15 09:09AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -11.69%
09:00AM  Rexahn Announces $7.0 Million Registered Direct Offering GlobeNewswire
Nov-05-15 09:07AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin® at the 14th International Kidney Cancer Symposium GlobeNewswire
Nov-04-15 07:47AM  4 Stocks Under $10 Making Big Up Moves on Big Volume at TheStreet
Nov-03-15 09:37AM  Rexahn reports 3Q loss +8.38%
09:00AM  Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update GlobeNewswire
Nov-02-15 04:46PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Oct-26-15 09:13AM  Rexahn Pharmaceuticals Receives U.S. Patent for RX-3117 Anti-Cancer Program GlobeNewswire
Oct-14-15 09:00AM  Rexahn Pharmaceuticals to Present at the 14th Annual BIO Investor Forum GlobeNewswire
Sep-30-15 09:00AM  Rexahn's Human Data Confirms Anti-Cancer Advantage Accesswire
Sep-28-15 09:13AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -13.11%
09:00AM  Rexahn Pharmaceuticals Presents Preliminary Clinical Data for Supinoxin(TM) and RX-3117 Oncology Programs at the European Cancer Congress 2015 GlobeNewswire
Sep-25-15 09:00AM  Rexahn Pharmaceuticals to Present Preliminary Clinical Data at the European Cancer Congress 2015 GlobeNewswire
Sep-23-15 09:00AM  Rexahn Pharmaceuticals to Present at the 15th Annual Biotech in Europe Investor Forum GlobeNewswire
Sep-10-15 09:01AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-08-15 09:01AM  Rexahn Pharmaceuticals to Present at the Biopharm America(TM) 2015 Conference in Boston GlobeNewswire
Aug-31-15 09:00AM  Rexahn Pharmaceuticals to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 10, 2015 GlobeNewswire
Aug-10-15 09:24AM  Rexahn reports 2Q loss
09:00AM  Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-15 08:13PM  10-Q for Rexahn Pharmaceuticals, Inc. at Company Spotlight
Aug-07-15 06:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Jul-17-15 04:13PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jul-14-15 09:02AM  Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform GlobeNewswire +10.91%
Jun-22-15 09:00AM  Rexahn Announces the Appointment of Peter Brandt as Chairman of the Board GlobeNewswire
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer, and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma. In addition, the company is involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ahn Chang HoDirectorApr 10Option Exercise0.31250,00077,5006,260,000Apr 12 05:26 PM
Ahn Chang HoDirectorApr 10Sale0.70250,000175,3756,010,000Apr 12 05:26 PM